Brief: Aquestive Therapeutics Inc Received Notice Of Failure To Satisfy A Continued Listing Rule Or Standard From Nasdaq
03/01/2023 18:45
Jan 3 (Reuters) - Aquestive Therapeutics Inc AQST.O :
* AQUESTIVE THERAPEUTICS INC - ON DEC 30, 2022, CO RECEIVED NOTICE OF
FAILURE TO
SATISFY A CONTINUED LISTING RULE OR STANDARD FROM NASDAQ
Further company coverage: AQST.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Aquestive Therapeutics
See all newsBrief: Aquestive Therapeutics Inc - Enters Five-Year Term Loan Facility Of Up To $150 Million On May 12, 2026 - SEC Filing
Aquestive Therapeutics Q1 revenue jumps on higher license and royalty income
Brief: Aquestive Therapeutics Announces Completion Of Type A Meeting With FDA For Anaphylm™ (Dibutepinephrine) Sublingual Film
Aquestive misses Q4 revenue estimates, EBITDA loss widens
Brief: Aquestive Therapeutics, Inc. Q4 Net Income USD -31.86 Million